RXST Q1 2025: Q2 Softness, H2 Recovery Expected, Margins to 71-73%
- Strong H2 Recovery Catalysts: Executives expect the impact of intensified commercial initiatives and a stabilization in procedure volumes later in the year, suggesting that LAL procedure volumes could rebound in H2 despite current macro headwinds.
- International Expansion Potential: Positive regulatory milestones in key markets like South Korea and anticipated approvals in the U.K. and parts of Europe indicate robust growth opportunities outside the U.S..
- Robust Pipeline and Technology Differentiation: The company’s long-term focus on expanding its adjustable lens technology—including next-generation multifocal and accommodative solutions—provides a strong foundation for sustained premium segment growth.
- Macroeconomic Uncertainty Delaying Revenue Recovery: Management indicated that near‐term volume growth, particularly in Q2, was expected to be weak and that any contribution from new commercial efforts would likely only impact the back half of the year, given ongoing macroeconomic headwinds and market turmoil.
- Operational and Workload Challenges Hindering Adoption: Several responses highlighted persistent workload challenges at practices, with staffing and process changes impeding the rapid adoption of the LAL technology, potentially delaying procedure growth.
- Competitive Pressures and Trialing Concerns: The Q&A underscored competitive trialing from fixed premium IOLs and evolving market dynamics, which could erode the uniqueness of the LAL and pressure margins if differentiation fails to resonate with all surgeons.
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Revenue | FY 2025 | $185 million to $197 million, YoY growth 32%–41% | $160 million to $175 million, YoY growth 14%–25% | lowered |
Gross Margin | FY 2025 | 71%–73% | 71%–73% | no change |
Operating Expenses | FY 2025 | $165 million to $170 million | $150 million to $160 million | lowered |
Non-cash Stock-based Compensation Expenses | FY 2025 | $22 million to $25 million | $27 million to $30 million | raised |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Procedure utilization and adoption trends | Mentioned as an initial acceleration in adoption with seasonal deceleration concerns and expected recovery in Q3 2024 and Q2 2024. | Emphasized early acceleration followed by deceleration due to macroeconomic headwinds with signs of recovery later in the quarter. | Recurring topic with increasing emphasis on the impact of macroeconomic factors affecting early procedure volumes. |
International expansion and regulatory developments | Consistently discussed in Q3 2024 with global regulatory processes and market entry strategies and addressed complexities in Q2 2024. | Focused on full regulatory approvals in South Korea and progress in Europe (including an upcoming U.K. approval), highlighting clear market opportunities. | Evolving from uncertainty to accelerating regulatory progress with targeted market entries. |
Product innovation and technology differentiation | Highlighted in Q3 2024 through the rollout of LAL+ and enhanced outcomes and emphasized in Q2 2024 with LAL+ and adjustable lens advancements. | Expanded to include software updates, pipeline expansion, and exploration of future lens types, alongside regulatory milestones. | Steady emphasis with enhanced technological differentiation and a broader innovation focus. |
Operational and workload challenges hindering adoption | Touched upon in Q3 2024 through practice integration narratives while Q2 2024 focused on improved training and workflow integration without explicit challenges. | More explicit discussion of staffing challenges and postoperative adjustment concerns noted by physicians, emphasizing barriers to adoption. | Increased focus as a growing adoption barrier with more targeted educational and operational support initiatives. |
Competitive pressures from alternative premium IOL offerings | Not explicitly detailed in Q3 2024 and absent in Q2 2024 discussions. | Notable commentary on competitive trialing and structural market shifts lowering differentiation, impacting procedure volumes. | Emerging as a heightened concern that is driving the company to reinforce its unique, customizable technology. |
Macroeconomic and external environment risks | In Q3 2024, external factors included hurricane impacts causing temporary volume dips , while Q2 2024 did not mention external risks. | Emphasized macroeconomic headwinds causing a decline in LAL procedure volumes; no mention of hurricane impacts. | A shift from weather‐related risks to broader macroeconomic uncertainty, with evolving sentiment on external factors. |
Capital economics and financial payback metrics | Detailed in Q3 2024 with explanations of a 6‐month return on LDD investments and indirectly discussed in Q2 2024 regarding premium procedure profitability. | Not specifically discussed in Q1 2025 [N/A]. | Topic appears to be less emphasized in the current period. |
Market penetration and channel expansion | Discussed in Q3 2024 with a focus on expanding market share and engaging optometrists as a key channel, and in Q2 2024 with planned increases in optometrist outreach. | No specific mention of channel expansion or optometrist engagement in Q1 2025 [N/A]. | This area has diminished visibility in the current discussion. |
Seasonality and volume variability challenges | Addressed in Q3 2024 with typical seasonal dips due to vacations and hurricane impacts and noted in Q2 2024 as inherent in the installed base’s growth patterns. | Detailed atypical trends with flat procedure volumes early in the year and subsequent recovery, influenced by macroeconomic turmoil. | Persisting challenge with changed seasonality patterns as external economic pressures modify historic seasonal trends. |
Operating expense and margin pressures | Covered in Q3 2024 with rising SG&A and R&D expenses alongside improved gross margins and in Q2 2024 with similar cost increases and margin guidance adjustments. | Q1 2025 shows further increases in operating expenses (SG&A and R&D) with stable yet pressured margins, though gross margin improvements were noted. | Continued cost pressures remain a key focus, with management balancing higher investments against stable gross margins. |
-
Commercial Timing
Q: When will commercial efforts pay off?
A: Management expects the impact of redoubled commercial efforts to materialize in the back half of the year as macro headwinds ease and procedure volumes improve. -
Gross Margin Guidance
Q: Will margin benefits continue in Q2?
A: While strong production volume boosted margins to 74.8% in Q1, adjustments in production and inventory mean expected margins for later periods will settle in the 71–73% range. -
Quarterly Cadence
Q: How will Q2 revenue compare to Q1?
A: Management cautions that Q2 may be softer than usual due to ongoing macro and competitive pressures, with significant recovery anticipated in the second half. -
International Expansion
Q: What is the strategy for international markets?
A: A market-by-market approach is in place, with some regions using local distributors (e.g., South Korea) and approvals like in the U.K. expected soon. -
Market Saturation
Q: Is there U.S. LAL saturation risk?
A: Current adoption stands at roughly 10–12%, leaving considerable room for growth among the approximately 10,000 U.S. cataract surgeons. -
Pipeline Insight
Q: Are multifocal and accommodating LALs feasible?
A: The technology’s adjustability is seen as a platform to expand into multifocal and accommodating lenses over the long term, offering a strong pipeline opportunity. -
Customer Scheduling Visibility
Q: Can Q2 procedure schedules be reliably forecasted?
A: Visibility depends on near real-time implant reporting rather than detailed scheduling, leaving some uncertainty that is closely monitored. -
Freestanding Centers
Q: What progress on freestanding LDD centers?
A: The initiative is in early stages with several third-party centers developing, modeled after successful LASIK service centers. -
Workload Challenges
Q: What causes practice workload issues?
A: Staffing challenges, a long-recognized issue in practices, are being addressed through enhanced clinical education and operational support.
Research analysts covering RxSight.